Shares of EyePoint Pharmaceuticals dropped nearly 30% premarket on Monday after the company said its experimental eye disease ...

Q1 2024 Revenue: Reported at $92.8 million, a 34.9% increase year-over-year, surpassing the estimated $85.6 million. Net Loss ...

Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z ...

NRx Pharmaceuticals, Inc. (NRXP) reported a statistically significant safety advantage of NRX-101 compared to the standard of care ...

By Denny Jacob EyePoint Pharmaceuticals said that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic ...

EyePoint Pharmaceuticals shares slide 32% after disclosing that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified ...

Attorney General Raoul announces a settlement with Amneal Pharmaceuticals over their role in the opioid crisis.

Q1 EPS of -$0.42 beats by $0.07 Ended first quarter 2024 with $321.0 million in cash, cash equivalents and investments; cash ...

Investors might want to bet on Rocket Pharmaceuticals (NASDAQ: RCKT), as it has been recently upgraded to a Zacks Rank #2 ...

Amneal Pharmaceuticals will pay $270 million for its alleged role in the national opioid epidemic, NYS Attorney General ...

X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in ...

With this latest development, Alembic Pharmaceuticals Limited holds EIRs for all its US FDA-regulated facilities.